STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- Cantargia AB
today announce that new preclinical data on the antibody CAN04 is
presented at the 11th annual PEGS (Protein &
Antibody Engineering Summit) Europe conference, Nov
18-22 in Lisbon, Portugal.
CAN04 is in clinical development for cancer and is designed to
enhance immune-mediated tumor cell killing. The new results show
that similar design applied to CAN04 surrogate antibodies enhance
antitumor effects in experimental cancer models and further support
for the strategy chosen.
Cantargia develops antibody-based pharmaceuticals against
interleukin-1 receptor accessory protein (IL1RAP). The antibody
CAN04 binds IL1RAP with high affinity and functions through both
Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of
interleukin 1 signaling. CAN04 is investigated in an open label
three-armed phase I/IIa clinical trial, CANFOUR. Two arms
investigate safety and efficacy of CAN04 in combination with two
different first line chemotherapy regimes in patients with
non-small cell lung cancer or pancreatic cancer (NCT03267316,
www.clinicaltrials.gov). A third arm investigates safety and
biomarkers of CAN04 monotherapy in patients with late stage
disease. One additional trial, investigating CAN04 with an immune
checkpoint inhibitor is planned to start early 2020.
Cantargia has previously presented anti-tumour effects in mice
using surrogate antibodies of CAN04. So far, these data have been
generated using non-modified antibody constructs. CAN04 is however
an ADCC-enhanced antibody lacking fucose produced by the
Potelligent® technology. The new results show that similar
modifications can be introduced in mouse surrogate antibodies.
Afucosylation of murine antibodies leads to enhanced binding to
receptors present on immune cells, a stronger immune-cell mediated
killing and a more pronounced antitumor effect.
The PEGS conference is a key annual conference around novel
antibody designs and strategies for development. The poster
entitled "Glycoengineered Murine Antibodies as Surrogates to the
Humanized and ADCC-enhanced Anti-IL1RAP Antibody CAN04
(nidanilimab)" is presented by Dr Camilla Rydberg Millrud, and Dr
David Liberg. The poster can be
downloaded at www.cantargia.com.
"These novel results give further evidence that the strategy
to include ADCC-enhancement is of importance and increase our
confidence in CAN04", Göran Forsberg, Cantargia's CEO
says.
For further information, please contact
Göran
Forsberg
CEO
Telephone: +46 (0)46-275-62-60
E-mail: goran.forsberg@cantargia.com
This is information that Cantargia AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, at 08.30 CET on 18
November 2019.
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology
company that develops antibody-based treatments for
life-threatening diseases. The basis for this is the protein IL1RAP
that is involved in a number of diseases and where Cantargia has
established a platform. The main project, the antibody CAN04
(nidanilimab) is being studied in the clinical phase I/IIa CANFOUR
with a primary focus on non-small cell lung cancer and pancreatic
cancer. The study is conducting both monotherapy and combination
therapy. Cantargia's other project, CANxx, is in the research phase
and is aiming to develop a IL1RAP binding antibody optimised for
the treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More
information about Cantargia is available at
http://www.cantargia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/cantargia-ab/r/cantargia-presents-novel-preclinical-data-on-antibody-can04-at-pegs-europe-conference,c2962996
The following files are available for download:
https://mb.cision.com/Main/7470/2962996/1142297.pdf
|
Release
|